Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant DOS (docetaxel, oxaliplatin, S-1) for unresectable lymph-node–limited gastric cancer
KCT0006894Phase 2Recruiting
- Sponsor
- Boryung
- Start
- May 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, oxaliplatin, tegafur in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Boryung. Started May 2022; status: recruiting.
02
Drugs
docetaxeloxaliplatintegafur
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on KCT0006894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006894.